Test Compound | n | IC50 | IP50ral (for SDZ-PSC833, IP2.5ral and for LY335979 IP1ral) | Concentration Needed to Double Baseline Fluorescence (f2) |
---|---|---|---|---|
μM | μM | |||
SDZ-PSC833 | 3 | N.D. | 1.32 ± 0.31** | 0.33 ± 0.04 |
LY335979 | 3 | 0.18 ± 0.10* | 1.22 ± 0.29** | 0.02 ± 0.01 |
Verapamil | 4 | 18.9 ± 4.2 | 0.84 ± 0.14 | 3.91 ± 1.78 |
Quinidine | 4 | 33.8 ± 11.9 | 0.88 ± 0.14 | 10.8 ± 1.9** |
Citalopram | 3 | N.D. | 0.05 ± 0.03** | 157.4 ± 56.8 |
Desmethylcitalopram | 3 | N.D. | 0.04 ± 0.02** | 133.5 ± 9.4** |
Fluoxetine | 4 | 115.5 ± 11.7** | 0.08 ± 0.06** | 91.4 ± 7.7** |
Norfluoxetine | 3 | N.D. | 0.08 ± 0.01** | 59.0 ± 16.1** |
Fluvoxamine | 4 | N.D. | 0.07 ± 0.04** | 64.0 ± 16.8** |
Paroxetine | 4 | 29.8 ± 11.1 | 0.37 ± 0.04** | 14.3 ± 3.5 |
Paroxetine-M | 3 | N.D. | 0.07 ± 0.03** | 97.2 ± 31.2** |
Reboxetine | 4 | N.D. | 0.12 ± 0.03** | 71.8 ± 17.8** |
Sertraline | 4 | 31.8 ± 2.8 | 0.83 ± 0.08 | 10.0 ± 0.9 |
Desmethylsertraline | 3 | N.D. | 0.49 ± 0.22 | 23.1 ± 5.6 |
Venlafaxine | 5 | N.D. | 0.01 ± 0.01** | N.D. |
N-desmethyl-venlafaxine | 3 | N.D. | 0.004 ± 0.005 | 440 ± 78 |
O-desmethyl-venlafaxine | 2 | N.D. | N.D. | N.D. |
Values represent mean ± S.D. of at least three independent assays.p values are determined by ANOVA with Dunnett's multiple comparison test for post hoc pairwise comparison of the results with the verapamil control.
N.D., not definable; n, number of experiments, each performed in octuplet.
1-150 p < 0.05, **p < 0.01.